The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1436
ISSUE1436
February 17, 2014
Macitentan (Opsumit) for Pulmonary Arterial Hypertension
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Macitentan (Opsumit) for Pulmonary Arterial Hypertension
February 17, 2014 (Issue: 1436)
The FDA has approved macitentan (ma" si ten' tan; Opsumit
– Actelion), for oral treatment of pulmonary arterial
hypertension (PAH). Macitentan is the second nonselective
endothelin receptor antagonist approved for PAH. It is a derivative
of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.